COMMUNIQUÉS West-GlobeNewswire

Maple Leaf Announces Conditional Approval for Transfer Listing of Common Shares to the Aequitas NEO Exchange Inc.

27/02/2018 - 14:00

CALGARY, Alberta, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Maple Leaf Green World Inc. (“ Maple Leaf ” or the “ Company ”) (TSX-V: MGW ) (OTCQB:MGWFF) announces that, further to the Company’s press release dated February 6, [...]

BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger

27/02/2018 - 14:00

Provide Update on Key Benefits of Pending Merger and Comprehensive Evaluation of Strategic Opportunities Leading Up to Definitive Merger Agreement BioCryst and Idera Boards of Directors Unanimously Recommend Respective [...]

Vital Therapies Announces Upcoming Fourth Quarter and Full Year Financial Results Conference Call with Webcast and Participation in Upcoming Conference

27/02/2018 - 13:59

SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL ), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release [...]

ICC Labs Receives Two Additional Medicinal Cannabis Licenses in Colombia

27/02/2018 - 13:30

Highlights: The Ministry of Justice and Law of the Republic of Colombia granted ICC Labs a license for the cultivation of psychoactive (high-THC) cannabis plants. The Ministry of Health of the Republic of Colombia [...]

XORTX Therapeutics Provides Corporate Update

27/02/2018 - 13:30

CALGARY, Alberta, Feb. 27, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney [...]

Actinium Pharmaceuticals Announces Activation of Sixteenth Clinical Trial Site in the Pivotal Phase 3 SIERRA Trial for Iomab-B

27/02/2018 - 13:30

- Current clinical trial sites represent over one-third of bone marrow transplant volume in the U.S. - Actinium expects continued site additions to support enrollment and trial completion objectives NEW YORK, Feb. 27, [...]

Alimera Sciences to Present at the 38th Annual Cowen & Co. Health Care Conference

27/02/2018 - 13:30

ATLANTA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, [...]

Cutera to Present at Two Upcoming Healthcare Conferences

27/02/2018 - 13:30

BRISBANE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq: CUTR ), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, announced today that James Reinstein, [...]

Misonix to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference on March 6

27/02/2018 - 13:30

FARMINGDALE, N.Y., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON ) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, [...]

Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio

27/02/2018 - 13:30

TORONTO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V: ARCH ) (OTCBB: ACHFF ) a portfolio-based biotechnology company, today announced CSBio of Menlo Park, California, has [...]

AxoGen Named Employee Engagement Best Practices Award Winner by DecisionWise International

27/02/2018 - 13:10

ALACHUA, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced it has received a 2018 [...]

ADMA Biologics to Present at Raymond James’ 39th Annual Institutional Investors Conference

27/02/2018 - 13:08

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA ) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, [...]

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

27/02/2018 - 13:05

SALT LAKE CITY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled [...]

AxoGen, Inc. to Present at 30th Annual ROTH Conference

27/02/2018 - 13:00

ALACHUA, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Karen Zaderej, [...]

Recro Pharma Reports Year End 2017 Financial Results

27/02/2018 - 13:00

IV Meloxicam NDA Submitted and PDUFA Action Date Set for May 26, 2018 Record CDMO Performance; 2017 Revenues of $71.8 Million MALVERN, Pa., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq: REPH ), a revenue [...]

ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer

27/02/2018 - 13:00

LEIDEN, the Netherlands, Feb. 27, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe [...]

Oxford Immunotec Reports Fourth Quarter and Full Year 2017 Financial Results

27/02/2018 - 13:00

2017 marks the 13 th consecutive year of at least 20% year-over-year constant currency revenue growth >25% pro forma organic growth for the year in tick-borne disease and other revenue Balance sheet strengthened by [...]

AMAG Reports 2017 Financial Results and Company Update

27/02/2018 - 13:00

2017 GAAP Revenue Increased 15% Year-over-Year February 2018: Company Secures Two U.S. Food and Drug Administration (FDA) Approvals Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM, Mass., Feb. 27, 2018 (GLOBE [...]

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress

27/02/2018 - 13:00

– Initiated two Phase 3 clinical studies to evaluate tab-cel™ (tabelecleucel) in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) who have failed rituximab and opened [...]